Bio-Path Holdings, Inc. (BPTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
BPTH Stock Price Chart Interactive Chart >
BPTH Price/Volume Stats
| Current price | $1.47 | 52-week high | $4.48 |
| Prev. close | $1.56 | 52-week low | $1.27 |
| Day low | $1.46 | Volume | 17,462 |
| Day high | $1.56 | Avg. volume | 37,579 |
| 50-day MA | $1.85 | Dividend yield | N/A |
| 200-day MA | $2.76 | Market Cap | 11.70M |
Bio-Path Holdings, Inc. (BPTH) Company Bio
Bio-Path Holdings, Inc. focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. The company was founded in 2007 and is based in Bellaire, Texas.
Latest BPTH News From Around the Web
Below are the latest news stories about BIO-PATH HOLDINGS INC that investors may wish to consider to help them evaluate BPTH as an investment opportunity.
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2022 Earnings Call TranscriptBio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2022 Earnings Call Transcript November 15, 2022 Bio-Path Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.49 EPS, expectations were $-0.45. Operator: Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode. Following […] |
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid TumorsPhase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast CancerHOUSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the enrollment and dosing of the first patient in a Phase 1/1b clinical trial of BP1 |
H.C. Wainwright Reaffirms Their Buy Rating on Bio-Path Holdings (BPTH)H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings (BPTH - Research Report) today and set a price target of $9.00. The company's shares opened today at $1.57.Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -28.1% and a 24.40% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Path Holdings with a $9.00 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.28 and a one-year low of $1.29. |
Bio-Path Holdings Reports Third Quarter 2022 Financial ResultsConference Call to be Held Today at 8:30 A.M. ETHOUSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent corporate developments. “The third quarter was marked by continued progress across |
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, November 15, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview. To access the live con |
BPTH Price Returns
| 1-mo | -23.04% |
| 3-mo | 7.30% |
| 6-mo | -58.88% |
| 1-year | -58.36% |
| 3-year | -57.88% |
| 5-year | -95.78% |
| YTD | -2.65% |
| 2022 | -59.95% |
| 2021 | 7.71% |
| 2020 | -56.20% |
| 2019 | 128.29% |
| 2018 | -91.25% |
Loading social stream, please wait...